The promise of gene therapy in head and neck cancer

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 4, Issue 2, 1996, Pages 82-87

  Mobley, Steven R ^a   Clayman, Gary L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; GENE THERAPY; HEAD AND NECK CANCER; HISTORY; HUMAN; IMMUNOMODULATION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0029999104     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/00020840-199604000-00003     Document Type: Review

References (37)

1. American Cancer Facts and Figures. Washington, DC: American Cancer Society; 1993.
2. Anderson WF: Human gene therapy [review]. Science 1992, 256:808-813.
3. Miller AD: Human gene therapy comes of age [review]. Nature 1992, 357:455-460.
4. Rosenberg SA: Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Eng J Med 1990, 323:570-578.
5. Nabel EG, Nabel GJ: Direct gene transfer: basic studies and human therapies [review]. Thromb Haemost 1993, 70:202-203.
6. Yoshimura K, Rosenfeld MA, Nakamura H, Scherer EM, Pavirani A, Lecocq J, Crystal RG: Expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung after in vitro intratracheal plasmid-mediated gene transfer. Nucleic Acids Res 1992, 20:3233-3240.
7. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL: Direct transfer into mouse muscle in vivo. Science 1991, 247:1465-1468.
8. Lasic DD, Papahadjopoulos D: Liposomes revisited. Science 1995, 267:1275-1276.
9. Spooner RA, Deonarain MP, Epenetos AA: DNA vaccination for cancer treatment Gene Therapy 1995, 2:173-180.
10. Berkner KL: Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988, 6:616-629.
11. Kozarsky KF, Wilson JM: Gene therapy: adenovirus vectors [review]. Curr Opin Genet Dev 1993, 3:499-503.
12. Strauss SE: Adenovirus infection in humans. In The Adenoviruses. Edited by Ginsber HS. New York: Plenum Press; 1984:451-496.
13. Chanock RM, Ludwig W, Heubner RJ, Gate TR, Chu L: Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA 1966, 195:151-165.
14. Cortesina G, Antonella DS, Sacchi M, Rosso S, Galeazzi E: Immunomodulation therapy for squamous cell carcinoma of the head and neck. Head Neck 1993, 15:266-270.
15. Kasid A, Morecki S, Aebersold P: Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci U S A 1990, 87:473-477.
16. Nabel GJ, Chang A, Nabel EG, Plautz G: Immunotherapy of malignancy by in vivo gene transfer into humans. Hum Gene Ther 1992, 3:399-410.
17. Rosenberg SA, Lotze MT, Yang JC: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210:474-485.
18. Rosenberg SA: Karnofsky memorial lecture: the immunotherapy and gene therapy of cancer [review]. J Clin Oncol 1992, 10:180-199.
19. Valone FH, Gandara DR, Deisseroth AB: Interleukin-2, cisplatin, 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother 1991, 10:207-213.
20. Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Lure J, Paradise C: Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother 1991, 10:207-213.
21. Urba S, Forastiere AA, Amerein PC, Wolf GT, Zeffren J: Phase II pilot study of concomitantly administered recombinant human interleukin-2 and Roferon A in patients with locally recurrent or metastatic head and neck cancer. Proc Annu Meet Am Soc Clin Oncol 1989, 8:A660.
22. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986, 46:5276-5281.
23. O'Malley BW Jr, Chen SH, Schwartz MR, Woo SL: Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995, 55:1080-1085. This is one of the few papers in the literature addressing the use of gene therapy for head and neck cancer. The authors show that the herpes simplex thymidine kinase gene can suppress the growth of SCCHN in a nude mouse model.
24. Garver RI, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT: Strategy for achieving selective killing of carcinomas. Gene Ther 1994, 1:46-50.
25. Moolten FL: Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994, 1:279-287.
26. Stetler G, Brewer MT, Thompson RC: Isolation and sequence of a human gene encoding a potent inhibition of leukocyte protease. Nucleic Acids Res 1986, 14:7883-7896.
27. Abe T, Kobayashi N, Yoshimura K: Expression of the secretory leuko-protease inhibitor gene in epithelial cells. J Clin Invest 1991, 87:2207-2215.
28. Harris J, Hurst H, Sikora K: Transcriptional targeting and tumor-specific gene therapy for cancer. Gene Ther 1994, 1(suppl 2):s14.
29. Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S: Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995, 55:3105-3109.
30. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR: Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther 1994, 1:170-175.
31. Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995, 55:1-6. This paper explores the model of microscopic residual disease and the ability of p53 to suppress SCCHN growth in vivo using this model.
32. Weinberg RA: Tumor suppressor genes [review]. Science 1992, 254:1138-1145.
33. O'Malley BW Jr, Ledley FD: Somatic gene therapy in otolaryngology-head and neck surgery [review]. Arch Otolaryngol Head Neck Surg 1993, 119:1191-1197.
34. Somers KD, Merrick A, Lopez ME, Incognito LS, Schecter GL, Casey G: Frequent p53 mutations in head and neck cancer. Cancer Res 1992, 52:5997-6000.
35. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994, 54:3662-3667. This paper demonstrates that exogenous expression of wild-type p53 can suppress the growth of SCCHN both in vitro and in vivo.
36. Liu TJ, el-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995, 55:3117-3122.
37. Clayman GL, Trapnell BC, Mittereder N, Liu TJ, Eicher S, Zhang S, Shillitoe EJ: Transduction of normal and malignant epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther 1995, 2:105-111.